Metal Ion Homeostasis Dysregulation in Alzheimer's Disease

Overview

This experiment investigates the role of metal ion dysregulation (copper, zinc, iron) in amyloid aggregation and neurotoxicity in Alzheimer's disease. Metal ion homeostasis is disrupted in AD brains, and metal-ion interactions with Abeta may accelerate plaque formation while also generating reactive oxygen species.

Research Question

AD Gap #16: Role of metal ion dysregulation in amyloid aggregation

Overview

This experiment investigates the role of metal ion dysregulation (copper, zinc, iron) in amyloid aggregation and neurotoxicity in Alzheimer's disease. Metal ion homeostasis is disrupted in AD brains, and metal-ion interactions with Abeta may accelerate plaque formation while also generating reactive oxygen species.

Research Question

AD Gap #16: Role of metal ion dysregulation in amyloid aggregation

What is the relationship between metal ion dysregulation and amyloid aggregation, and can metal chelation therapies slow disease progression?

Hypothesis

Copper, zinc, and iron dysregulation accelerates Aβ aggregation through direct metal-Aβ interactions and generates oxidative stress. Restoring metal homeostasis through chelation or ion channel modulation will reduce amyloid pathology and neurodegeneration.

Experimental Design

Model System

• In vitro: Cell-free Aβ aggregation assays with defined metal ion concentrations
• Cellular: Human iPSC-derived neurons and astrocytes with metal homeostasis gene knockouts
• Animal: APP/PS1 mice crossed with metal transport gene mutants (e.g., ATP7A, ZIP14, DMT1)

Validation Protocol

Phase 1: Metal-Aβ Interaction Mapping

Phase 2: Cellular Metal Homeostasis

Phase 3: In Vivo Metal Modulation

Expected Outcomes

Feasibility Assessment

| Factor | Rating | Notes |
|--------|-------|-------|
| Technical feasibility | 8/10 | Well-established assays; metal quantification requires specialized equipment |
| Cost efficiency | 6/10 | ICP-MS and chelator synthesis add cost |
| Timeline | 12 months | In vitro (3 mo) + cellular (6 mo) + in vivo validation (6 mo) |
| Cross-disease value | 7/10 | Similar mechanisms in PD (iron) and ALS (copper) |

Cost Estimate

| Component | Cost (USD) |
|-----------|------------|
| Personnel (2 FTE × 12 mo) | $240,000 |
| Metal assays and ICP-MS | $80,000 |
| iPSC differentiation | $60,000 |
| Animal work (100 mice) | $40,000 |
| Chelator compounds | $20,000 |
| Total | $440,000 |

Key References

Score

Total Score: 65 (Rank 78)

| Dimension | Score |
|-----------|-------|
| Mechanistic Impact | 7 |
| Cure Proximity | 5 |
| Feasibility | 7 |
| Cost Efficiency | 6 |
| Timeline | 7 |
| Cross-Disease Value | 7 |
| Biomarker Enablement | 5 |
| Combinability | 6 |
| De-risking Value | 5 |
| Novelty | 6 |

Addressed Gap

• AD Knowledge Gap #16: Role of metal ion dysregulation in amyloid aggregation

See Also

• [ApoE4 Function in AD](/experiments/apoe4-function-alzheimers)](/experiments)
• [Viral Infection Mechanisms in AD](/experiments/viral-infection-alzheimers)](/experiments)
• [AD Knowledge Gaps Ranked](/gaps/ad-knowledge-gaps-ranked)